Hyloris Pharmaceuticals Future Growth
Future criteria checks 5/6
Hyloris Pharmaceuticals is forecast to grow earnings and revenue by 52.3% and 84.3% per annum respectively while EPS is expected to decline by 1.2% per annum.
Key information
52.3%
Earnings growth rate
-1.2%
EPS growth rate
| Pharmaceuticals earnings growth | 15.0% |
| Revenue growth rate | 84.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 59 | 8 | -20 | -4 | 2 |
| 12/31/2025 | 12 | -13 | -24 | -17 | 2 |
| 12/31/2024 | 8 | -14 | -15 | -14 | 2 |
| 12/31/2023 | 3 | -16 | -13 | -13 | N/A |
| 9/30/2023 | 2 | -15 | -12 | -11 | N/A |
| 6/30/2023 | 3 | -12 | -12 | -11 | N/A |
| 3/31/2023 | 3 | -12 | -13 | -12 | N/A |
| 12/31/2022 | 2 | -12 | -13 | -12 | N/A |
| 9/30/2022 | 3 | -10 | -11 | -10 | N/A |
| 6/30/2022 | 3 | -8 | -9 | -8 | N/A |
| 3/31/2022 | 3 | -10 | -11 | -10 | N/A |
| 12/31/2021 | 3 | -12 | -12 | -11 | N/A |
| 9/30/2021 | 2 | -12 | -13 | -13 | N/A |
| 6/30/2021 | 1 | -12 | -14 | -14 | N/A |
| 3/31/2021 | 1 | -10 | -7 | -7 | N/A |
| 12/31/2020 | 0 | -7 | -5 | -5 | N/A |
| 9/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 6/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 3/31/2020 | 0 | -6 | -8 | -6 | N/A |
| 12/31/2019 | 0 | -5 | -6 | -5 | N/A |
| 12/31/2018 | 0 | -6 | -5 | -5 | N/A |
| 12/31/2017 | 0 | -4 | -4 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0AB6 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: 0AB6 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0AB6 is expected to become profitable in the next 3 years.
Revenue vs Market: 0AB6's revenue (84.3% per year) is forecast to grow faster than the UK market (3.7% per year).
High Growth Revenue: 0AB6's revenue (84.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0AB6's Return on Equity is forecast to be high in 3 years time